MTOR and neoplasm: As observed in other gliomas, such as subependymal giant cell astrocytoma (SEGA), in which stopping the mammalian target of rapamycin mTOR inhibitors (mTORi) results in inevitable tumor regrowth, after the discontinuation of BRAFi, up to 75% of patients experienced rapid progression in a few weeks.